Primary pulmonary hypertension

New England Journal of Medicine

Volumn 336, Issue 2, 1997, Pages 111-117

  Rubin, Lewis J ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; NIFEDIPINE; PROSTACYCLIN;

ANTICOAGULATION; CLINICAL PROTOCOL; DIAGNOSTIC APPROACH ROUTE; DIURESIS; HUMAN; INCIDENCE; LUNG FUNCTION; LUNG TRANSPLANTATION; LUNG VASCULAR RESISTANCE; LUNG VENTILATION PERFUSION RATIO; ORAL DRUG ADMINISTRATION; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SERODIAGNOSIS; SURVIVAL; TREATMENT PLANNING; VASCULAR ENDOTHELIUM;

ALGORITHMS; ANTICOAGULANTS; HUMANS; HYPERTENSION, PULMONARY; INCIDENCE; LUNG TRANSPLANTATION; VASODILATOR AGENTS;

EID: 0031031440     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199701093360207     Document Type: Review

References (53)

1. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987;107:216-23.
2. Edwards BS, Weir EK, Edwards WD, Ludwig J, Dykoski RK, Edwards JE. Coexistent pulmonary and portal hypertension: morphologic and clinical features. J Am Coll Cardiol 1987;10:1233-8.
3. Petitpretz P, Brenot F, Azarian R, et al. Pulmonary hypertension in patients with human immunodeficiency virus infection: comparison with primary pulmonary hypertension. Circulation 1994;89:2722-7.
4. Schaiberger PH, Kennedy TC, Miller FC, Gal J, Petty TL. Pulmonary hypertension associated with long-term inhalation of "crank" methamphetamine. Chest 1993;104:614-6.
5. Brenot F, Herve P, Petitpretz P, Parent F, Duroux P, Simonneau G. Primary pulmonary hypertension and fenfluramine use. Br Heart J 1993;70: 537-41.
6. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996;335:609-16.
7. Rubin LJ, Barst RJ, Kaiser LR, et al. Primary pulmonary hypertension. Chest 1993;104:236-50.
8. Speich R, Jenni R, Opravil M, Pfab M, Russi EW. Primary pulmonary hypertension in HIV infection. Chest 1991;100:1268-71.
9. McDonnell PJ, Toye PA, Hutchins GM. Primary pulmonary hypertension and cirrhosis: are they related? Am Rev Respir Dis 1983;127:437-41.
10. Loyd JE, Atkinson JB, Pictra GG, Virmani R, Newman JH. Heterogeneity of pathologic lesions in familial primary pulmonary hypertension. Am Rev Respir Dis 1988;138:952-7.
11. Loyd JE, Butler MG, Foroud TM, Conneally PM, Phillips JA III, Newman JH. Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension. Am J Respir Crit Care Med 1995;152:93-7.
12. Wood P. Pulmonary hypertension with special reference to the vasoconstrictive factor. Br Heart J 1958;20:557-70.
13. Wagenvoort CA. Vasoconstriction and medial hypertrophy in pulmonary hypertension. Circulation 1960;22:535-46.
14. Palevsky HI, Schloo BL, Pietra GG, et al. Primary pulmonary hypertension: vascular structure, morphometry, and responsiveness to vasodilator agents. Circulation 1989;80:1207-21.
15. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992;327:70-5.
16. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995;333:214-21.
17. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732-9.
18. Voelkel NF, Tuder RM, Weir EK. Pathophysiology of primary pulmonary hypertension: from physiology to molecular mechanisms. In: Rubin LJ, Rich S, eds. Primary pulmonary hypertension. New York: Marcel Dekker, 1997:83-133.
19. Martin-Duran R, Larman M, Trugeda A, et al. Comparison of Doppler-determined elevated pulmonary arterial pressure with pressure measured at cardiac catheterization. Am J Cardiol 1986;57:859-63.
20. Rich S, Pietra GG, Kieras K, Hart K, Brundage BH. Primary pulmonary hypertension: radiographic and scintigraphic patterns of histologic subtypes. Ann Intern Med 1986;105:499-502.
21. Nicod P, Peterson K, Levine M, et al. Pulmonary angiography in severe chronic pulmonary hypertension. Ann Intern Med 1987;107:565-8.
22. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-301.
23. The wedge pressure in pulmonary veno-occlusive disease. In: Harris P, Heath D. The human pulmonary circulation. 2nd ed. Edinburgh, Scotland: Churchill Livingstone, 1977:651-2.
24. Bourdillon PD, Oakley CM. Regression of primary pulmonary hypertension. Br Heart J 1976;38:264-70.
25. Loogen F, Worth H, Schwan G, Goeckenjan G, Losse B, Horstkotte D. Long-term follow-up of pulmonary hypertension in patients with and without anorectic drug intake. Cor Vasa 1985;27:111-24.
26. Nall KC, Rubin LJ, Lipskind S, Sennesh JD. Reversible pulmonary hypertension associated with anorexigen use. Am J Med 1991;91:97-9. [Erratum, Am J Med 1991;91:670.]
27. Weir EK, Rubin LJ, Ayres SM, et al. The acute administration of vasodilators in primary pulmonary hypertension: experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. Am Rev Respir Dis 1989;140:1623-30.
28. Barst RJ. Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension. Chest 1986; 89:497-503.
29. Groves BM, Badesch DB, Turkevitch D, et al. Correlation of acute prostacyclin response in primary (unexplained) pulmonary hypertension with efficacy of treatment with calcium channel blockers and survival. In: Hume JR, Reeves JT, Weir EK, eds. Ion flux in pulmonary vascular control. New York: Plenum Press, 1993:317-30.
30. Pepke Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991;338:1173-4.
31. Rubin LJ, Groves BM, Reeves JT, Frosolono M, Handel F, Cato AE. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation 1982;66:334-8.
32. Morgan JM, McCormack DG, Griffiths MJD, Morgan CJ, Barnes PJ, Evans TW. Adenosine as a vasodilator in primary pulmonary hypertension. Circulation 1991;84:1145-9.
33. Sitbon O, Brenot F, Denjean A, et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension: a dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med 1995; 151:384-9.
34. Zobel G, Dacar D, Rodl S, Friehs I. Inhaled nitric oxide versus inhaled prostacyclin and intravenous versus inhaled prostacyclin in acute respiratory failure with pulmonary hypertension in piglets. Pediatr Res 1995;38:198-204.
35. Rich S, Brundage BH. High dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 1987;76:135-41.
36. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81.
37. Packer M, Medina N, Yushak M. Adverse hemodynamic and clinical effects of calcium channel blockade in pulmonary hypertension secondary to obliterative pulmonary vascular disease. J Am Coll Cardiol 1984;4:890-901.
38. Leier CV, Bambach D, Nelson S, et al. Captopril in primary pulmonary hypertension. Circulation 1983;67:155-61.
39. Melot C, Naeije R, Mols P, Vandenbossche JL, Denolin H. Effects of nifedipine on ventilation/perfusion matching in primary pulmonary hypertension. Chest 1983;83:203-7.
40. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994;121:409-15.
41. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomized trial. Ann Intern Med 1990;112:485-91.
42. Olschewski H, Walmrath D, Schermuly R, Ghofrani A, Grimminger F, Seeger W. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996;124:820-4.
43. Pasque MK, Trulock EP, Kaiser LR, Cooper JD. Single-lung transplantation for pulmonary hypertension: three-month hemodynamic follow-up. Circulation 1991;84:2275-9.
44. Higenbottam TW, Spiegelhalter D, Scott JP, et al. Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension. Br Heart J 1993;70:366-70.
45. Hosenpud JD, Novick RJ, Bennett LE, Keck BM, Fiol B, Daily OP. The Registry of the International Society for Heart and Lung Transplantation: thirteenth official report - 1996. J Heart Lung Transplant 1996;15:655-74.
46. Kshettry VR, Kroshus TJ, Savik K, Hertz MI, Bolman RM. Primary pulmonary hypertension as a risk factor for the development of obliterative bronchiolitis in lung allograft recipients. Chest 1996;110:704-9.
47. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984;70:580-7.
48. Kerstein D, Levy PS, Hsu DT, Hordof AJ, Gersony WM, Barst RJ. Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension. Circulation 1995;91:2028-35.
49. Nelson DM, Main E, Crafford W, Ahumada GG. Peripartum heart failure due to primary pulmonary hypertension. Obstet Gynecol 1983;62: Suppl:58S-63S.
50. Oakley C, Somerville J. Oral contraceptives and progressive pulmonary vascular disease. Lancet 1968;1:890-3.
51. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991;115:343-9.
52. 2 analogue, beraprost, in primary and secondary pulmonary hypertension. Am J Cardiol 1996;78:244-7.
53. Snell GI, Salamonsen RF, Bergin P, Esmore DS, Khan S, Williams TJ. Inhaled nitric oxide used as a bridge to heart-lung transplantation in a patient with end-stage pulmonary hypertension. Am J Respir Crit Care Med 1995;151:1263-6.